This year, our list of top stories includes coverage of studies on breast, lung, gastrointestinal, and genitourinary cancers as well as malignant and benign hematology. It is always challenging to identify only 10 key papers from the universe of important new data, but these summaries underscore our goal of identifying the most clinically relevant trials and highlighting their key findings and implications.
We look forward to continuing to bring you concise summaries of the most important research in oncology and hematology during the coming year.
The top NEJM Journal Watch Oncology and Hematology stories for 2022 are:
Avoiding Chemotherapy in ER-Positive, Node-Positive Breast Cancer
Immunotherapy plus Chemotherapy Before Surgery Improves Outco…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)